Insulin glargine market
Insulin Glargine Market, By Type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
- Mar 2024
- CMI5231
- 167 Pages
- Excel & Pdf
- Pharmaceutical
Summary
N/A
Table of Content
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Global Insulin Glargine Market– Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Global Insulin Glargine Market, By Type, 2019-2031, (USD BN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Introduction
- Global Insulin Glargine Market, By Diabetes Type, 2019-2031, (USD BN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Introduction
- Global Insulin Glargine Market, By Distribution Channel, 2019-2031, (USD BN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Introduction
- Global Insulin Glargine Market, By Region, 2019-2031, (USD BN)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 – 2031
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
*Browse 24 market data tables and 28 figures on "Global Insulin Glargine Market” –forecast to 2031
Segmentation
Detailed Segmentation
- Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
- Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Frequently Asked Questions -
What will be the CAGR of global insulin glargine market during the forecast period?
The CAGR of global insulin glargine market is projected to be 6.4% from 2024 to 2031.
What are the major factors driving the global insulin glargine market growth?
Rise in prevalence of diabetes and increase in demand for insulin glargine are the major factor driving the growth of global insulin glargine market.
What are the key factors hampering growth of the global insulin glargine market?
High cost of insulin glargine and introduction of or availability of insulin biosimilars are the major factor hampering the growth of global insulin glargine market.
Which is the leading type segment in the global insulin glargine market?
In terms of type, lantus segment estimated to dominate the market in 2024.
Which are the major players operating in the global insulin glargine market?
Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, Viatris Inc. are the major players.
Which region will lead the global insulin glargine market?
North America is expected to lead the global insulin glargine market.